ABSTRACT
The European Society of Cardiology guidelines on cardio-oncology
The guidelines on cardio-oncology published by the European Society of Cardiology (ESC) in 2022 provide an in-depth compendium of knowledge on possible cardiovascular complications of anticancer treatment, which have been extensively discussed. The guidelines contain relevant definitions and recommendations concerning the diagnosis, treatment and prevention of cancer therapy-related cardiovascular toxicity (CTR-CVT) as well as the management of cardiovascular (CV) disease caused directly or indirectly by cancer and cancer treatment. The guidelines discuss the assessment of baseline risk, prevention and monitoring during cancer treatment, management of CTR-CVT assessment of CV risk during end-of-cancer therapy, and long-term control of high-risk cancer survivors. There is also an overview of the principles of cardiac control during the use of seven different cancer therapies, including anthracyclines and anti-HER2 drugs, and a plan proposed for follow-up cardiovascular examinations oriented towards pediatric and adult cancer survivors. The document features an excellent graphical layout and contains a number of useful tables and algorithms. Given the dynamic development of oncology and hematology in the last two decades, the guidelines are a must-have in the scientific library of every cardiology specialist.
Piśmiennictwo
1. Lyon AR, López-Fernández T, Couch LS, et al.; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43(41):4229-361
2. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al.; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37(36):2768-801
3. Lyon A, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 2020;22(11):1945-60
4. Konstantinides S, Meyer G, Becattini C, et al.; The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2019;00:1-61
5. Sturgeon K, Deng L, Bluethmann S, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 2019;40:3889-97
6. Hundley WG, D’Agostino R, Crotts T, et al. Statins and left ventricular ejection fraction following doxorubicin treatment. NEJM Evid 2022;1(9):10.1056/evidoa2200097